Skip to main content
. 2004 Jun 14;101(25):9363–9368. doi: 10.1073/pnas.0403271101

Table 2. Survey of DR2-restricted T cell responses among NY-ESO-1 IMX-vaccinated patients.

NY-ESO-1/DR2 responses
NY-ESO-1/DP4 responses
Patient Anti-ESO antibody HLA-DR2 T cells % CD4+ prevaccination T cells % CD4+ postvaccination HLA-DP4 T cells % CD4+ postvaccination
5 + + N/A + 0.22 0.03
7 + + N/A + 2.46 + + 1.07
9 + 0 0.006 NT
10 + + 0.033 + 0.44 + +/— 0.065
13 + +/— 0.066 + 0.12 + 0.017
24 + + 0.015 + 0.18 + 0.018
16 + +/— 0.068 NT + +/— 0.062
17 + + 0.023 + 0.27 0.01
19 + NT 0.008 + 0.016
21 + 0.023 0.012 0

Postvaccination samples from listed patients were tested for the DR2-restricted (NY-ESO-186—99) and DP4-restricted (NY-ESO-1157—170) responses after a 13-day culture. The positive samples were then repeated side by side with prevaccination samples, if available. Eight DR2-positive samples (six of which were also DP4+) from normal individuals were also tested for the two T cell specificities, and the results were all negative (not listed). Intracellular cytokine staining values (shown as percentage of CD4+ cells) from all negative controls were <0.03% of total gated CD4+ cells. The definite positive results are in bold. +/— potential but weak responses. NT, not tested; N/A, sample not available.